For 30 days, migraineurs were randomized to an FDA-approved dental device to help jaw clenching or a placebo device.
Findings of a randomized-controlled trial suggest intense nocturnal jaw clenching may serve as a contributing factor to headache-related disability among patients with chronic migraine. Results were published in BMC Neurology, and also confirm a nociceptive trigeminal inhibition (NTI) oral device is one method of assessing whether jaw-clenching contributes to ongoing migraine.
Chronic migraineurs can be refractive to multiple preventive medications while others may be reluctant to use pharmacotherapeutic treatments due to their systemic side effects, researchers explained.
Although the exact underlying pathology of migraine is unknown, the condition is thought to involve overactivity in the trigeminal-occipital-cervical complex of the nerves.
Previous research has implicated habitual nocturnal jaw clenching as a potential migraine trigger, especially among those who have headaches upon waking up or shortly afterwards.
To help address his condition, the NTI was developed to minimize clenching intensity and subsequent afferent nociceptive activity. “The NTI is a semi-custom intraoral mouthpiece approved by the FDA in 2001 for the prophylactic treatment of medically diagnosed migraine pain through reduction of trigeminally-innervated muscular activity,” authors wrote.
In an effort to assess efficacy of the NTI splint in improving disability, researchers conducted a single blind study among 25 chronic migraineurs who presented to a headache center.
All participants were referred to a dental practice to be considered for the study and were treated with both a placebo device and an NTI device, however, “the participants were not aware of which device was FDA approved, while practitioners were familiar with the NTI.”
At baseline, patients completed a Headache Impact Test (HIT-6) questionnaire. After being randomized to either 30 days of NTI splint use or placebo splint use, patients completed another HIT-6 questionnaire and switched to the alternate device. They then completed a final questionnaire after the second 30-day use period.
Of the 25 participants, 19 completed the full trial and patients’ initial average HIT-6 score was 4 or “severe impact, disabling pain.”
Analyses revealed:
“Decreasing peripheral sensitization with modalities such as the NTI splint protocol which reduces chronic nociceptive input can help to decrease central sensitization, which is a hallmark of chronic migraine,” authors wrote.
Although it was approved over 2 decades ago, the NTI has not become a commonly used adjunctive preventive treatment for migraine, potentially due to patients’ negative experiences with traditional dental splints or a lack of knowledge among providers.
“The production of nociceptive input by the affected teeth, bone, [temporomandibular joints] and muscles to the trigeminal sensory nucleus produced by nocturnal jaw clenching should be considered as a potential perpetuating and confounding co-factor of Chronic Migraine,” researchers concluded.
Reference:
Blumenfeld AM, and Boyd JP. Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study. BMC Neurology. Published online March 4, 2022. doi:10.1186/s12883-022-02591-8
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
2 Commerce Drive
Cranbury, NJ 08512